Literature DB >> 6973588

Anti-double strand (ds) DNA antibody formation by NZB/W (F1) spleen cells in a microculture system detected by solid phase radioimmunoassay.

H Okudaira, E Terada, T Ogita, S Aotsuka, R Yokohari.   

Abstract

A solid-phase radioimmunoassay method was devised to detect mouse anti-double strand (ds) DNA antibody. This method could easily detect the anti-dsDNA antibody in 1 : 10,000 dilutions (1 unit) of pooled 9-10-month-old female NZB/W F1 sera. The sensitivity was about 10(3)- and 10(2)-fold higher than that of the modified Farr method and of the double antibody technique respectively. NZB/W mice developed high titer anti-dsDNA antibody as they grew older. Spleen cells brought to a microculture system using flat-bottomed polystyrene plates produced anti-dsDNA antibody clearly detectable by solid-phase radioimmunoassay. Anti-dsDNA antibody produced in vitro (y units) was in close correlation with the anti-dsDNA antibody titer of the spleen donor (x units) (y = 4.8 X 10(-2) x -65, gamma = 0.94, P less than 0.001). A combination of the microculture system and solid-phase radioimmunoassay was recommended for the characterization of anti-dsDNA antibody-forming cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6973588     DOI: 10.1016/0022-1759(81)90243-x

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Adsorption of anti-dsDNA antibodies by immobilized polyanionic compounds.

Authors:  S Aotsuka; T Funahashi; N Tani; M Okawa-Takatsuji; M Kinoshita; R Yokohari
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

2.  Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis.

Authors:  M Shiraki; M Fujiwara; S Tomura
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

3.  Analysis of negatively charged dye-binding antibodies reactive with double-stranded DNA and heparan sulfate in serum from patients with rheumatic diseases.

Authors:  S Aotsuka; M Okawa-Takatsuji; M Kinoshita; R Yokohari
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.